Generics

News Generics

• IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014

  IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion (ex manufacturer prices) over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading produc more

• Sartorius opens new plant in India

  Sartorius inaugurated its new plant at the Sartorius Group’s location in Bangalore, India. Together with some 100 guests from the scientific community and politics, CEO Dr. Joachim Kreuzburg, Supervisory Board Chairman Prof. Arnold Picot and Managing Director of Sartorius India Amit Chatterjee offic more

• Dr. Bernhard Hampl joins ChemWerth Board of Directors

  Peter Werth, the President and CEO of US-based ChemWerth Inc, announced that Dr. Bernhard Hampl has joined the company’s board of directors. Dr. Hampl, received his Ph.D. in pharmaceutical chemistry from Ludwig-Maximillians University in Munich and his career has included working for Cyanamid GmbH more

White papers Generics

• Outsourcing R&D Innovation takes on New Meaning
  

  Innovative drugs are the lifeblood of pharmaceutical companies, but the cost of developing them is rising to unsustainable levels. Pharma executives are already saying that as the economy falters, they foresee bleak prospects and mergers unless their companies get more innovative drugs into their pipelines. The clock is ticking on the race to increase productivity, as key patents worth a projected $30 billion in revenue will expire between 2010 and 2013, opening the floodgates to competition from generics, according to Barbara Ryan, an analyst at Deutsche Bank. This imperative is propelling increased outsourcing of R&D operations as companies trim overcapacity. more

Publications Generics

• Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 1. Criticisms Faced by the Pharmaceutical Industry

  The pharmaceutical industry is facing enormous challenges, including reduced efficiency, declining innovation, key patent expirations, fierce price competition from generics, high regulatory hurdles, and a tarnished image. There is a clear need for change in the paradigms designed to address these c more

• Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers [Biochemistry]

  Chaperones are the primary regulators of the proteostasis network and are known to facilitate protein folding, inhibit protein aggregation, and promote disaggregation and clearance of misfolded aggregates inside cells. We have tested the effects of five chaperones on the toxicity of misfolded oligom more

• A new approach to comparison of original pharmaceuticals and generics based on comparison of multidimensional impurity profiles using supercritical fluid extraction, liquid ext ...

  This paper reports on our effort to study the possibility of comparing the original pharmaceuticals and their analogs (generics) based on comparisons of the multidimensional profiles of impurities isolated from samples by supercritical fluid extraction and liquid extraction and recorded by gas chrom more

Market studies Generics

• Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region

  GBI Research’s report, “Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region" provides detailed insight into the Americas API market. The research presents detailed analysis and for more

• Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Major ...

  GBI Research’s report, “Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity” provides detailed insight into the Europe API market. The researc more

• Venezuela Pharmaceuticals and Healthcare Report Q1 2011

  BMI calculates that pharmaceutical sales in Venezuela, under pressure from economic and pricing factors, reached VEB12.76bn (US$5.95bn) in 2009, a 31.2% local currency year-on-year (y-o-y) increase. However, this was largely because of double-digit inflation levels, rather than a reflection of true more

Websites Generics